[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"advanced-gastric-carcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:advanced-gastric-carcinoma":42},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,8,0,[8,74,139,163,207,236,259,281],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":54,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":62,"lastUpdatePostDateStruct":63,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":73},"100561192","phase-1-a-study-with-nkt3964-for-adults-with-advancedmetastatic-solid-tumors-100561192",false,"NCT06586957","A Study With NKT3964 for Adults With Advanced\u002FMetastatic Solid Tumors","A Phase 1, First-in-human, Open-label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral CDK2 Degrader NKT3964 in Adults With Advanced\u002FMetastatic Solid Tumors","Inclusion Criteria:\n\n\\- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only: subjects must be refractory to, or intolerant of existing therapy(ies) known to provide clinical benefit for their condition.\n\nDose Escalation:\n\n1. Ovarian cancer\n2. Endometrial cancer (only endometrioid subtype will require CCNE1 amplification)\n3. Gastric, gastroesophageal junction (GEJ) or esophageal adenocarcinoma with CCNE1 amplification\n4. Small cell lung cancer (SCLC)\n5. Triple-negative breast cancer (TNBC; HER2, estrogen receptor and progesterone receptor negative)\n6. HR+ (includes estrogen-receptor or progesterone-receptor) and HER2- breast cancer (must have progressed following treatment with a CDK4\u002F6 inhibitor, and is not suitable for endocrine therapy \\[ET\\])\n7. Other solid tumors with CCNE1 amplification\n\nDose Expansion:\n\nPart 2A: HR+ and HER2- breast cancer that is locally advanced and unresectable (Stage III) or metastatic (Stage IV); previously treated with ≥1 line of standard of care (SOC) including CDK4\u002F6 inhibitor plus ET and not suitable for further ET. Subjects must have progressed after receiving therapy for ≥3 months in the metastatic setting or for ≥6 months in the adjuvant setting. Subjects must have received ≤2 lines of systemic cytotoxic therapy (chemotherapy or cytotoxic antibody drug conjugate \\[ADC\\]) in the metastatic setting..\n\nPart 2B: Advanced platinum-based-chemotherapy resistant or refractory epithelial ovarian\u002Ffallopian\u002Fprimary peritoneal carcinoma or clear cell ovarian cancer (defined as recurrence ≤6 months after completing platinum-based regimen) with progression on at least one platinum containing therapy and previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease and with CCNE1 amplification.\n\nPart 2C: Advanced unresectable or metastatic gastric, GEJ or esophageal adenocarcinoma with progression on at least one systemic therapy and previously treated with ≤3 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease, with CCNE1 amplification as determined by NGS by local liquid or tissue test.\n\nPart 2D: Advanced endometrial adenocarcinoma or uterine papillary serous carcinoma previously treated with ≤4 prior lines of systemic therapy administered for advanced\u002Fmetastatic disease with CCNE1 amplification.\n\nPart 2E: Advanced\u002Frecurrent uterine carcinosarcoma previously treated with 1 prior platinum-based chemotherapy regimen and ≤3 prior lines of systemic therapy. Prior bevacizumab or PARP inhibitors are allowed and must be at least 3 weeks prior to the start of study drug.\n\n* Have adequate organ function\n* Subjects with female reproductive organs must be surgically sterile, post-menopausal, or must be willing to use highly effective method(s) of contraception\n* Ability to swallow oral medications.\n* Consent to provide archived tumor tissues and paired tumor biopsy at pretreatment\n\nExclusion Criteria:\n\n* Locally advanced solid tumor that is a candidate for curative treatment through radical surgery and\u002For radiotherapy, or chemotherapy.\n* History of another malignancy with exceptions\n* History of lymphohistiocytic or lymphoid hyperplasia; hemophagocytic lymphohistiocytosis.\n* Failed to recover from effects of prior anticancer treatment therapy to baseline or Grade ≤ 1 severity (per CTCAE)\n* Clinically significant cardiovascular event within 6 months prior to start of NKT3964 treatment\n* Known active CNS metastases and\u002For carcinomatous meningitis\n* Active interstitial lung disease currently requiring treatment\n* History of uveitis, retinopathy or other clinically significant retinal disease\n* Active or chronic corneal disorders, other active ocular conditions requiring ongoing therapy, or any clinically significant corneal disease\n* Active wound healing from major surgery within 1 month or minor surgery within 10 days before the first dose of NKT3964.\n* Known human immunodeficiency virus (HIV), active hepatitis B or C infection\n* Prior investigative treatment with a selective or nonselective CDK2 inhibitor or degrader\n* Childs-Pugh class B or C cirrhosis or any other clinically significant liver disorder\n* Palliative radiation therapy within 14 days or other radiation therapy within 4 weeks prior to C1D1","ALL","18 Years",{"count":19,"type":20},150,"ESTIMATED","INTERVENTIONAL",[23],"PHASE1","The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D).",[26,27,28,29,30,31,32,33,34,35,36,37,38,39,40,41,42,43,44,45,46,47,48,49,50,51,52,53],"Solid Tumor","Advanced Solid Tumor","Solid Tumor, Adult","Metastatic Tumor","Ovarian Cancer","Ovarian Neoplasms","Ovarian Carcinoma","Metastatic Ovarian Carcinoma","Endometrial Neoplasms","Endometrial Diseases","Metastatic Endometrial Cancer","Triple Negative Breast Cancer","Metastatic Endometrial Carcinoma","Advanced Endometrial Carcinoma","Advanced Ovarian Carcinoma","Gastric Cancer","Advanced Gastric Carcinoma","Metastatic Gastric Cancer","Metastatic Gastric Carcinoma","Small Cell Lung Cancer","Small Cell Lung Carcinoma","Triple Negative Breast Neoplasms","Platinum-resistant Ovarian Cancer","Platinum-refractory Ovarian Carcinoma","CCNE1 Amplification","Hormone Receptor Negative Breast Carcinoma","Human Epidermal Growth Factor 2 Negative Carcinoma of Breast","Progesterone-receptor-positive Breast Cancer",[55,56,57,58,59,60],"CDK 2 Inhibitor","CDK 4 Inhibitor","CDK 6 Inhibitor","CDK2 Degrader","Protein Degrader","PROTAC","RECRUITING","2026-04-16",{"date":64,"type":65},"2026-04-21","ACTUAL",{"date":67,"type":65},"2024-09-19",{"date":69,"type":20},"2029-05",{"name":71,"class":72},"NiKang Therapeutics, Inc.","INDUSTRY",19,{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":81,"targetDuration":4,"studyType":21,"phases":83,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":128,"lastUpdatePostDateStruct":129,"startDateStruct":131,"completionDateStruct":133,"leadSponsor":135,"locationsCount":138},"100513775","phase-2-at-home-cancer-directed-therapy-versus-in-clinic-for-the-treatment-of-patients-with-advanced-cancer-100513775","NCT05969860","At-Home Cancer Directed Therapy Versus in Clinic for the Treatment of Patients With Advanced Cancer","Cancer CARE Beyond Walls - A Pilot of a Randomized, Pragmatic Trial of Cancer Directed Therapy Administration in the Patients' Homes Versus in Clinic","Inclusion Criteria:\n\n* Female or male patients with histologically confirmed malignancy. Patients with hepatocellular carcinoma (HCC) are eligible based on imaging diagnosis along; histologic confirmation is not required.\n* Participant must be receiving a standard-of-care treatment regimen listed in this protocol that is being used in accordance with standard medical practice. Specifically, it must be either a) FDA-approved for the participant's disease indication, or b) recommended in nationally recognized professional guidelines (e.g. NCCN, ASCO, ASH, etc.) as standard of care for the disease indication. Off-label use is permitted only if supported by such guidelines.\n\n  * Note, patients diagnosed with any of the following disease types may receive any of the eligible regimens listed. Additionally, patients receiving immunotherapy, such as nivolumab or pembrolizumab, may receive these infusions in home supplemental to any of the regimens identified. Patients may receive any combination of any above listed medications or regimens:\n  * Eligible disease cancer types:\n\n    * Anal cancer\n    * Appendiceal carcinoma\n    * Basal cell carcinoma\n    * Bladder cancer\n    * Biliary cancer\n    * Breast cancer\n    * Central Nervous System malignancy including glioblastoma\n    * Cervical cancer\n    * Cholangiocarcinoma\n    * Colorectal carcinoma\n    * Endometrial cancer\n    * Fallopian tube cancer\n    * Gastroesophageal cancer \\[including gastric, esophageal, and gastroesophageal junction (GEJ) cancers\\]\n    * Germ cell carcinoma\n    * Head and Neck cancer\n    * Hepatocellular Carcinoma\n    * Liver\n    * Lung\n    * Lymphoma\n    * Melanoma\n    * Merkel Cell\n    * Multiple Myeloma\n    * Myelodysplastic syndrome\n    * Myeloid Disorders\n    * Neuroendocrine carcinoma\n    * Ovarian cancer\n    * Pancreatic adenocarcinoma\n    * Penile carcinoma\n    * Peritoneal carcinoma\n    * Prostate cancer\n    * Renal cell cancer\n    * Sarcoma\n    * Squamous cell Carcinoma of the Skin\n    * Testicular cancer\n    * Urethral carcinoma\n    * Vaginal carcinoma\n    * Vulvar carcinoma\n  * Eligible Regimens\n\n    * Fluorouracil (5-FU) +\u002F- leucovorin +\u002F- bevacizumab +\u002F- trastuzumab\n    * 5FU +\u002F- leucovorin +\u002F- bevacizumab +\u002F- nivolumab\n    * Atezolizumab +\u002F- bevacizumab\n    * Atezolizumab +\u002F- bevacizumab + cobimetinib, atezolizumab +\u002F- bevacizumab + vemurafenib, atezolizumab +\u002F- bevacizumab + cobimetinib + vemurafenib\n    * Avelumab\n    * Avelumab + axitinib\n    * Bevacizumab\n    * Bevacizumab + capecitabine\n    * Bevacizumab + irinotecan (+\u002F- capecitabine)\n    * Bevacizumab + olaparib, bevacizumab + lenvatinib, bevacizumab + niraparib, bevacizumab + rucaparib\n    * Bevacizumab + Temozolomide, Bevacizumab + Lomustine, or Bevacizumab + everolimus\n    * Bevacizumab + trifluridine\u002Ftipiracil\n    * Bortezomib\n    * Bortezomib + cyclophosphamide, bortezomib + lenalidomide, bortezomib + pomalidomide, bortezomib + selinexor\n    * Bortezomib + venetoclax\n    * Carfilzomib\n    * Carfilzomib + cyclophosphamide, carfilzomib + lenalidomide, carfilzomib + pomalidomide, carfilzomib + selinexor\n    * Carfilzomib + venetoclax\n    * Cemiplimab\n    * Cisplatin\n    * Cisplatin\u002F5-FU\n    * Cisplatin\u002Fetoposide\n    * Cisplatin + durvalumab\n    * Cisplatin + gemcitabine\n    * Cisplatin + gemcitabine + durvalumab\n    * Daratumumab (+ oral \\[PO\\] cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Daratumumab + bortezomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Daratumumab + carfilzomib (+ PO cyclophosphamide, lenalidomide, pomalidomide, or selinexor)\n    * Degarelix\n    * Durvalumab\n    * Durvalumab + tremelimumab\n    * Eribulin\n    * FOLFIRI +\u002F- bevacizumab (5FU +\u002F- leucovorin + irinotecan)\n    * Fam-trastuzumab deruxtecan\n    * Fulvestrant\n    * Fulvestrant + ribociclib, fulvestrant + abemaciclib, fulvestrant + palbociclib, fulvestrant + alpelisib, or fulvestrant + capivasertib\n    * Gemcitabine\n    * Gemcitabine + durvalumab\n    * Gemcitabine + paclitaxel protein-bound\n    * Goserelin acetate\n    * Irinotecan\n    * Irinotecan + capecitabine\n    * Lanreotide\n    * Leuprolide\n    * Nivolumab\n    * Nivolumab + cabozantinib\n    * Nivolumab-relatlimab\n    * Octreotide\n    * Paclitaxel\n    * Pembrolizumab\n    * Pembrolizumab + axitinib, pembrolizumab + lenvatinib, pembrolizumab + capecitabine, pembrolizumab + dabrafenib +\u002F- trametinib, pembrolizumab + trametinib)\n    * Pemetrexed\n    * Pertuzumab\n    * Pemetrexed + pembrolizumab\n    * Rituximab\n    * Trastuzumab + paclitaxel\n    * Trastuzumab with or without pertuzumab maintenance (SQ or IV) (+\u002F- tucatinib +\u002F- capecitabine)\n    * Decitabine\n    * These regimens can be used only if patients are receiving one of the regimens above:\n\n      * Darbepoetin-alfa\n      * Epoetin\n      * Filgrastim\n* Note: Female or male patients with histologically confirmed malignancy who are currently receiving treatment with one of the above eligible regimens may receive supportive care medications for treatment or prevention of bone metastases, including agents such as:\n\n  * Zoledronic acid\n  * Denosumab\n* Patient has had adequate tolerability of their clinical standard of care cancer treatment in the opinion of their treating physician and no drug-related infusion reactions prior to consent\n* Patients who according to documentation from their treating provider plan to continue the treatment regimen they are currently prescribed for at least 24 weeks from the start of cycle following randomization.\n* Residing within the area serviced by supplier and paramedic network\n* Residence has wireless fidelity (wifi) to enable a reliable connection with the remote Command Center or it is suitable for connection through a wireless network solution\n* Age \\>= 18 years at time of registration\n* Signed informed consent form by patient\n* Willing and able to comply with the study protocol in the investigator's judgement\n* Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) 0, 1 or 2\n* Ability to complete questionnaire(s) by themselves or with assistance\n* RANDOMIZATION ELIGIBILITY CRITERIA: In addition to the criteria above, confirmation by the CCBW Command Center that the patient has adequate tolerability to the standard of care cancer therapy and no drug-related infusion reactions since pre-registration and prior to registration\n\nExclusion Criteria:\n\n* Receiving any other investigational agent which would be considered as a treatment for the primary neoplasm. Note: Patients are permitted concomitant standard of care oral drugs such as ribociclib, abemaciclib, or palbociclib in combination with endocrine therapy (e.g., Leuprolide, fulvestrant intramuscular \\[IM\\], etc.); tucatinib and capecitabine in combination with trastuzumab and pertuzumab for HER2 positive breast cancer; dexamethasone, cyclophosphamide, lenalidomide or pomalidomide for multiple myeloma; temozolomide, lomustine, or afinitor in combination with avastin for glioblastoma. In addition, all oral anti-hormonal agents for breast and prostate cancer are permitted (e.g., tamoxifen, arimidex, abiraterone, etc.) if used in combination with any of the drugs\n* Requiring 24\u002F7 assistance with activities of daily living (ADLs)\n* Current inpatient hospitalization (excluding admission to the Advanced Care at Home program)\n* Co-morbid systemic illnesses or other severe concurrent disease which, in the judgment of the investigator, would make the patient inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens\n* Uncontrolled intercurrent illness including, but not limited to:\n\n  * Ongoing or active infection\n  * Symptomatic congestive heart failure\n  * Unstable angina pectoris\n  * Cardiac arrhythmia\n  * Myocardial infarction =\\\u003C 6 months\n  * Wound healing disorder\n  * Or psychiatric illness\u002Fsocial situations that would limit compliance with study requirements",{"count":82,"type":20},220,[84],"PHASE2","This clinical trial studies the effect of cancer directed therapy given at-home versus in the clinic for patients with cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Currently most drug-related cancer care is conducted in infusion centers or specialty hospitals, where patients spend many hours a day isolated from family, friends, and familiar surroundings. This separation adds to the physical, emotional, social, and financial burden for patients and their families. The logistics and costs of navigating cancer treatments have become a principal contributor to patients' reduced quality of life. It is therefore important to reduce the burden of cancer in the lives of patients and their caregivers, and a vital aspect of this involves moving beyond traditional hospital and clinic-based care and evaluate innovative care delivery models with virtual capabilities. Providing cancer treatment at-home, versus in the clinic, may help reduce psychological and financial distress and increase treatment compliance, especially for marginalized patients and communities.",[87,88,89,90,91,92,93,42,94,95,96,97,98,99,100,101,40,102,103,104,105,106,107,108,109,39,110,111,112,113,114,115,116,117,118,119,120,121,122,123,124,125,126,127],"Advanced Anal Carcinoma","Advanced Biliary Tract Carcinoma","Advanced Bladder Carcinoma","Advanced Breast Carcinoma","Advanced Carcinoid Tumor","Advanced Cervical Carcinoma","Advanced Colorectal Carcinoma","Advanced Glioblastoma","Advanced Head and Neck Carcinoma","Advanced HER2 Positive Breast Carcinoma","Advanced Lung Carcinoma","Advanced Lung Small Cell Carcinoma","Advanced Malignant Germ Cell Tumor","Advanced Malignant Solid Neoplasm","Advanced Neuroendocrine Carcinoma","Advanced Pancreatic Carcinoma","Advanced Prostate Small Cell Neuroendocrine Carcinoma","Advanced Prostate Carcinoma","Hematopoietic and Lymphoid System Neoplasm","Multiple Myeloma","Myelodysplastic Syndrome","Advanced Basal Cell Carcinoma","Advanced Cholangiocarcinoma","Advanced Esophageal Carcinoma","Advanced Fallopian Tube Carcinoma","Advanced Hepatocellular Carcinoma","Advanced Liver Carcinoma","Advanced Lymphoma","Advanced Malignant Testicular Neoplasm","Advanced Melanoma","Advanced Merkel Cell Carcinoma","Advanced Penile Carcinoma","Advanced Primary Malignant Central Nervous System Neoplasm","Advanced Renal Cell Carcinoma","Advanced Sarcoma","Advanced Skin Squamous Cell Carcinoma","Advanced Urethral Carcinoma","Advanced Vaginal Carcinoma","Advanced Vulvar Carcinoma","Advanced Appendix Carcinoma","Advanced Gastroesophageal Junction Adenocarcinoma","2026-04-15",{"date":130,"type":65},"2026-04-20",{"date":132,"type":65},"2023-08-23",{"date":134,"type":20},"2027-01-01",{"name":136,"class":137},"Mayo Clinic","OTHER",2,{"id":140,"slug":141,"hasResults":11,"nctId":142,"briefTitle":143,"officialTitle":144,"acronym":4,"eligibilityCriteria":145,"healthyVolunteers":11,"sex":16,"minAge":146,"maxAge":4,"enrollmentInfo":147,"targetDuration":4,"studyType":21,"phases":149,"briefSummary":151,"conditions":152,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":153,"lastUpdatePostDateStruct":154,"startDateStruct":156,"completionDateStruct":158,"leadSponsor":160,"locationsCount":162},"100456636","phase-3-efficacy-and-safety-of-ferric-carboxymaltose-in-patients-with-advanced-gastric-cancereffect-agc-100456636","NCT05226169","Efficacy and Safety oF FErric CarboxymalTose in Patients With Advanced Gastric Cancer(EFFECT-AGC)","Randomized Controlled Trial of Intravenous Ferric Carboxymaltose for Iron-Deficiency Anemia in Patients With Advanced Gastric Cancer Receiving Palliative Chemotherapy","Inclusion Criteria:\n\n1. Age ≥ 19 years at the time of study registration\n2. Eastern Cooperative Oncology Group performance status ≤ 2\n3. Histologically or cytologically confirmed gastric or gastroesophageal junction (GEJ) adenocarcinoma\n4. Locally advanced unresectable or metastatic disease\n5. Patients who have not been treated with palliative systemic antitumor agents for advanced or recurrent gastric or GEJ adenocarcinoma\n6. Patients scheduled to receive palliative first-line fluoropyrimidine and platinum-based systemic therapy including targeted therapy or immunotherapy\n7. Life expectancy ≥24 weeks\n8. IDA\n\n   1. Hb 8 to \\\u003C11 g\u002FdL\n   2. Absolute ID (serum ferritin \\\u003C 100 ng\u002FmL) OR functional ID (TSAT\\* \\\u003C 50% and serum ferritin 100-500 ng\u002FmL)\n\n      * TSAT = (serum iron level x 100)\u002F total iron-binding capacity (TIBC)\n\nExclusion Criteria:\n\n1. Body weight \\\u003C 35 kg\n2. Immediate need for transfusion or Hb \\\u003C 8 g\u002FdL\n3. Possible functional ID or No ID (serum ferritin \\> 500 ng\u002FmL OR TSAT ≥ 50%)\n4. Anemia attributable to factors other than cancer or chemotherapy (e.g., vitamin B12 and\u002For serum folate deficiency; hemolysis; or myelodysplastic syndromes)\n5. Ongoing bleeding or overt gross active bleeding (e.g., hematemesis, melena, or hematochezia)\n6. Neoplastic bone marrow infiltration\n7. History of ESA, IV or oral iron therapy, and\u002For RBC transfusion 4 weeks prior to randomization\n8. Iron overload or disturbances in utilization of iron (e.g., personal or family history of hemochromatosis and hemosiderosis)\n9. Known hypersensitivity to any of the required study products or known serious hypersensitivity to other parenteral iron products\n10. Known severe allergies including drug allergies, history of severe asthma, eczema or other atopic allergies, and in subjects with immune or inflammatory conditions (e.g., systemic lupus erythematosus, rheumatoid arthritis)\n11. Decreased renal function including renal dialysis (previous, current or planned within the next 6 months,) or serum creatinine levels ≥ 2.0 mg\u002FdL, or estimated glomerular filtration rate \\\u003C 30 mL\u002Fmin\u002F1.73 m2\n12. Chronic liver disease (including active hepatitis) and\u002For aspartate transaminase (AST) or alanine transaminase (ALT) ≥ 3 times the upper limit of the normal range\n13. Active acute or chronic infections (assessed by clinical judgment)\n14. Other significant medical condition(s) in the opinion of the investigator with an anticipated need for major surgery during the study, or any other kind of disorder that may be associated with increased risk to the subject or may interfere with study assessments, outcomes (e.g., uncontrolled hypertension, active cardiac disease, thromboembolic disease, or uncontrolled diabetes mellitus, neurological or psychiatric disorders)\n15. Pregnancy (e.g., positive human chorionic gonadotropin test) or breast-feeding. If the subject is of childbearing potential and does, not use adequate contraceptive precautions. The subject must agree to use adequate contraception during the study and for 1 month after the last dose of study treatment. A highly effective method of birth control must be used.","19 Years",{"count":148,"type":20},330,[150],"PHASE3","The main objective of this study is to evaluate the efficacy and safety of IV FCM(ferric carboxymaltose) in patients with AGC receiving palliative chemotherapy. This study will also evaluate the effect of IV FCM on the treatment outcomes of palliative chemotherapy in patients with gastric cancer receiving fluoropyrimidine and platinum-based regimen in the same 1st-line palliative setting.",[42],"2026-04-02",{"date":155,"type":65},"2026-04-03",{"date":157,"type":65},"2022-04-29",{"date":159,"type":20},"2026-11-30",{"name":161,"class":137},"Asan Medical Center",1,{"id":164,"slug":165,"hasResults":11,"nctId":166,"briefTitle":167,"officialTitle":168,"acronym":169,"eligibilityCriteria":170,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":171,"enrollmentInfo":172,"targetDuration":4,"studyType":21,"phases":173,"briefSummary":174,"conditions":175,"keywords":189,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":201,"completionDateStruct":203,"leadSponsor":205,"locationsCount":138},"100518299","phase-2-total-neoadjuvant-flot-chemotherapy-in-locally-advanced-gastric-and-gastroesophageal-junction-cancer-100518299","NCT06028737","Total Neoadjuvant FLOT Chemotherapy in Locally Advanced Gastric and Gastroesophageal Junction Cancer","Total Neoadjuvant Chemotherapy With 5-fluoruracil, Leucovorin, Oxaliplatin, and Docetaxel in Locally Advanced Gastric and Gastroesophageal Junction Cancer (OCTASUR): Randomized, Multi-center, Open-label Trial, Phase 2\u002F3","OCTASUR","Inclusion Criteria:\n\n* Tumor spread according to TNM: ≥cT3 and\u002For ≥cN0 and M0 (except of invasion of the common hepatic artery, celiac trunk, proximal part of the splenic artery, aorta, head of the pancreas);\n* Performance status by Eastern Cooperative Oncology Group (ECOG): 0 - 1;\n* Histologically confirmed gastric adenocarcinoma or gastroesophageal junction (Siewert type 2\u002F3) adenocarcinoma.\n* Differentiation grade: G0 - G4;\n* Tumor localization: cardio-esophageal junction (Siewert 2, 3), cardiac part of the stomach, body of the stomach, antral part of the stomach, pyloric part of the stomach;\n* Tumor extension: esophagus, diaphragm, liver, body and tail of the pancreas, anterior abdominal wall, small and large intestine, distal part of the splenic artery, spleen;\n* Patient agrees to participate in this biomedical study.\n\nExclusion Criteria:\n\n* Presence of another oncological disease at a different site if less than 5 years have passed since radical treatment.\n* Comorbidities or patient conditions that preclude the administration of chemotherapy.","80 Years",{"count":19,"type":20},[84,150],"The main goal of this study is to investigate the proportion of participants with locally advanced gastric and gastroesophageal adenocarcinoma without previous treatment during the last 5 years who can tolerate all planned cycles of chemotherapy and radical surgical treatment who will be prospectively randomized into two groups to undergo one of two chemotherapy regimens, followed by surgery:\n\n1. 8 cycles of Total Neoadjuvant ChemoTherapy (TNT) with 5-Fluorouracil (5-FU), Leucovorin, Oxaliplatin, and Docetaxel (FLOT) followed by surgery.\n2. 4 cycles of Neoadjuvant FLOT chemotherapy scheme preoperatively and 4 adjuvant FLOT cycles postoperatively.",[41,176,177,178,179,180,181,182,183,127,42,184,185,186,187,188],"Stomach Cancer","GastroEsophageal Cancer","Gastric Adenocarcinoma","Gastroesophageal Junction Adenocarcinoma","Advanced Gastric Adenocarcinoma","Gastric Neoplasm","Stomach Neoplasm","Gastrointestinal Cancer","Chemotherapy","Gastrectomy","Gastrectomy for Gastric Cancer","Gastric Resection","Gastric (Cardia, Body) Cancer",[190,191,192,185,193,194,195,196,197],"Total neoadjuvant chemotherapy","FLOT","Fluoruracil","Perioperative chemotherapy","Docetaxel","Leucovorin","Gastric resection","Gastric cancer","2025-04-30",{"date":200,"type":65},"2025-05-06",{"date":202,"type":65},"2025-03-25",{"date":204,"type":20},"2032-12-31",{"name":206,"class":137},"Ukrainian Society of Clinical Oncology",{"id":208,"slug":209,"hasResults":11,"nctId":210,"briefTitle":211,"officialTitle":212,"acronym":4,"eligibilityCriteria":213,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":215,"targetDuration":4,"studyType":21,"phases":217,"briefSummary":218,"conditions":219,"keywords":221,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":227,"lastUpdatePostDateStruct":228,"startDateStruct":230,"completionDateStruct":232,"leadSponsor":234,"locationsCount":162},"100567282","phase-2-shr-a1811-combined-with-apatinib-in-the-treatment-of-advanced-gastric-or-gastroesophageal-junction-adenocarcinoma-and-colorectal-cancer-100567282","NCT06666166","SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","Exploratory Clinical Study of SHR-A1811 Combined with Apatinib in the Treatment of Advanced Gastric or Gastroesophageal Junction Adenocarcinoma and Colorectal Cancer","Inclusion Criteria:\n\n1. Participants voluntarily enrolled in this study and signed an informed consent form, were compliant and co-operated with follow-up visits;\n2. Age 18-75 years, including 18 and 75 year, male and female;\n3. ECOG (Eastern Cooperative Oncology Group) performance status of 0-1;\n4. Has a life expectancy of greater than 3 months;\n5. Cohort A: Has histologically confirmed diagnosis of unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;\n6. Cohort B: Has histologically confirmed diagnosis of unresectable, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma;\n7. There must be a measurable target lesion that meets the RECIST 1.1 criteria;\n8. The function of major organs meets the following criteria(not transfused, not using haematopoietic factors and not corrected with drugs within 14 days):\n\n   1. Absolute neutrophil count (ANC) ≥1.5×10\\^9\u002FL;\n   2. PLT ≥100×10\\^9\u002FL;\n   3. Hb≥9g\u002FdL;\n   4. ALB≥3.0g\u002FdL;\n   5. total bilirubin ≤1.5 x ULN;\n   6. ALT\u002FAST ≤ 2.5 x ULN (When there is liver metastasis, ALT\u002FAST ≤ 5 x ULN);\n   7. Serum creatinine (Cr) ≤1.5×ULN or creatinine clearance (CCr) ≥60mL\u002Fmin (according to Cockcroft-Gault formula);\n   8. prothrombin time (PT) and activated partial thromboplastin time (APTT) ≤1.5×ULN;\n   9. Echocardiography （ECHO）\u002FCardiac radionuclide scan （MUGA showed i.LVEF≥50%);\n   10. Urine routine results showed that urine protein \\\u003C1+; For patients with urine protein ≥2+ at baseline, 24-hour urine collection and 24-hour urine protein quantification \\\u003C1g should be performed.\n9. Females of childbearing potential must have a negative serum or urine pregnancy test within 72 hours prior to the first dose and agree to use a highly effective method of contraception for the duration of the study up to 6 months after the last administration of study drug. Male subjects whose partner is a female of childbearing potential must agree to use a highly effective method of contraception for the duration of the study up to 6 months after the last administration of study drug.\n\nExclusion Criteria:\n\n1. Patients with meningeal metastases; Or patients with brain metastases that have not been treated with surgery or radiation, but those who have been stable for at least one month after treatment and have stopped using steroid drugs (such as 10mg\u002Fday prednisone or other equivalent hormones) for more than 2 weeks except;\n2. Uncontrolled pleural effusion or ascites;\n3. There are serious concomitant diseases: such as serious cardiovascular and cerebrovascular disease, kidney failure, liver failure, hematopoietic disease, endocrine disease, cachexia, etc;\n4. Previously received antibody drug conjugate therapy containing topoisomerase I inhibitors, such as trastuzumab deruxtecan (DS-8201), etc; Subjects underwent surgery (except diagnostic surgery), radiotherapy, chemotherapy, macromolecular targeted therapy or immunotherapy within 4 weeks before the first dose of the study drug；Small molecule targeted drugs (including other oral targeted drugs used in clinical trials) whose last dose is less than 5 half-life period or 4 weeks (whichever is shorter) from the first dose; Subjects received palliative radiotherapy or local treatment less than 2 weeks after completion of treatment and before the first dose;\n5. Subjects who have been treated with live vaccine or attenuated vaccine within 1 month prior to the first dose;\n6. Subjects requiring systemic therapy with corticosteroids (\\>10 mg\u002Fday of prednisone or equivalent) or other immunosuppressive agents within 14 days prior to first dose, excluding nasal spray or inhaled corticosteroids.\n7. The toxicity caused by previous anti-tumor treatments has not recovered to ≤ CTCAE grade 1 (excluding hair loss; according to the researcher's judgment, some tolerable chronic grade II toxicity can be excluded);\n8. Uncontrolled hypertension (systolic blood pressure ≥ 150 mmHg or diastolic blood pressure ≥ 100 mmHg); Active bleeding (such as local active ulcer lesions and fecal occult blood≥ ++), with a history of gastrointestinal bleeding within 6 months;\n9. Abnormal coagulation function (INR\\>1.5 or prothrombin time (PT)\\>ULN+4 seconds or APTT\\>1.5 × ULN), with a tendency to bleed or undergoing thrombolytic or anticoagulant therapy;\n10. Subjects were co-administered a potent CYP3A4 or CYP2D6 inhibitor or inducer within 3 weeks prior to first dosing;\n11. Factors affecting oral administration of medications such as inability to swallow, chronic diarrhoea and intestinal obstruction;\n12. Any active autoimmune disease or history of autoimmune disease (e.g., autoimmune hepatitis, uveitis, enteritis, pituitary gland inflammation, vasculitis, myocarditis, nephritis, hyperthyroidism, hypothyroidism (may be included after hormone replacement therapy)); and skin disorders (e.g., vitiligo, psoriasis, or alopecia) in which asthma has been in complete remission in childhood and has required no intervention in adulthood or in which systemic therapy is not required.subjects with autoimmune mediated hypothyroidism treated with thyroid replacement hormone at a stable dose and type I diabetes patients treated with insulin at a stable dose can be included;\n13. Subjects with immunodeficiency disease, such as HIV infection, congenital or acquired immune dysfunction, organ transplantation；\n14. Uncontrolled heart clinical symptoms or diseases, such as (1) New York Heart Association class II or higher heart failure; (2) unstable angina pectoris; (3) Myocardial ischaemia within 1 year; (4) Subjects with clinically significant supraventricular or ventricular arrhythmias requiring clinical intervention;\n15. Complicated severe infection within 30 days prior to first dose, including but not limited to infection complications that require hospitalization, bacteremia, severe pneumonia, etc; active infections that have received therapeutic intravenous antibiotics within 2 weeks prior to the first dose. Subjects receiving prophylactic antibiotic treatment (such as preventing urinary tract infections) can be enrolled;\n16. Subjects with active hepatitis B (HBsAg positive with HBV DNA ≥ 500 IU\u002Fml), hepatitis C (hepatitis C antibody positive with HCV-RNA above the lower limit of detection of the analytical method);\n17. Evidence of previously clinically significant lung diseases, including but not limited to interstitial pneumonitis, pneumonitis, pulmonary fibrosis and radiographic pneumonia (Excluding radioactive changes do not require treatment), or suspected subjects with this type of diseases founded during the screening period;\n18. Allergy to any investigational drug or its excipients;\n19. Concomitant other malignancies ≤5 years prior to enrollment, except adequately treatable carcinoma in situ of the cervix, basal cell or squamous epithelial cell skin cancer, localised prostate cancer, and ductal carcinoma;\n20. Serious physical or mental illnesses or laboratory abnormalities. Any condition which, in the opinion of the Investigator, may be detrimental to the subject or result in the subject's inability to meet or perform the requirements of the study.","75 Years",{"count":216,"type":20},28,[84],"To evaluate the effectiveness and safety of SHR-A1811 combined with apatinib in the treatment of advanced gastric or gastroesophageal junction adenocarcinoma and colorectal cancer.",[42,127,220],"Advanced Colorectal Cancer",[222,223,224,225],"apatinib","advanced gastric or gastroesophageal junction adenocarcinoma","advanced colorectal cancer","SHR-A1811","NOT_YET_RECRUITING","2024-10-29",{"date":229,"type":65},"2024-10-30",{"date":231,"type":20},"2024-12",{"date":233,"type":20},"2028-12",{"name":235,"class":137},"Yunpeng Liu",{"id":237,"slug":238,"hasResults":11,"nctId":239,"briefTitle":240,"officialTitle":241,"acronym":4,"eligibilityCriteria":242,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":243,"targetDuration":4,"studyType":244,"phases":4,"briefSummary":245,"conditions":246,"keywords":247,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":250,"lastUpdatePostDateStruct":251,"startDateStruct":253,"completionDateStruct":255,"leadSponsor":257,"locationsCount":162},"100565490","multi-omics-based-prediction-of-treatment-response-to-immunotherapy-combined-with-chemotherapy-in-advanced-gastricgastroesophageal-junction-cancer-100565490","NCT06642857","Multi-omics Based Prediction of Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric\u002FGastroesophageal Junction Cancer.","Predicting Treatment Response to Immunotherapy Combined with Chemotherapy in Advanced Gastric\u002Fgastroesophageal Junction Cancer Based on the Multi-omics Information During Tumor Evolution.","Inclusion criteria：\n\n* Patients with gastric or gastroesophageal junction adenocarcinoma confirmed by pathology and with advanced or metastatic disease that cannot be resected\n* HER2 negative\n* Not received any anti-tumor treatment before.\n* After evaluation, the treatment plan is chemotherapy combined with immunotherapy.\n* Aged 18 to 75 years old, gender is not limited.\n* Expected survival time is greater than or equal to 3 months. Exclusion criteria：\n* Patients with malignant tumors other than gastric cancer or those with tumors metastasized to the stomach from other sites.\n* Patients who have previously received anti-tumor treatments such as surgery, radiotherapy and chemotherapy, targeted therapy or immunotherapy.\n* Patients with severe infections.\n* Those with a history of mental illness cannot cooperate with the research.\n* Patients with severe heart, liver, kidney and other diseases.\n* Pregnant or lactating patients.\n* HER2 positive.",{"count":19,"type":20},"OBSERVATIONAL","In this project, based on the information of advanced gastric\u002Fgastroesophageal junction cancer in evolution under immunotherapy combined with chemotherapy treatment, we will integrate multi-omics dynamic data to identify essential features that correlate to therapeutic effects of immunotherapy therapy, screen potential molecular markers\u002Fdominant microbiota for predicting the efficacy of immunotherapy and establish a multimodal predictive model for patients that benefit from immunotherapy. Our project could provide evidence to predict response to immunotherapy for patients with advanced gastric\u002Fgastroesophageal junction cancer and potentially optimize the clinical decision-making about therapy for advanced gastric\u002Fgastroesophageal junction cancer.",[42,127],[42,127,248,249],"Chemotherapy combined with immunotherapy","efficacy prediction","2024-10-14",{"date":252,"type":65},"2024-10-15",{"date":254,"type":65},"2024-03-25",{"date":256,"type":20},"2026-02-01",{"name":258,"class":137},"Xiangdong Cheng",{"id":260,"slug":261,"hasResults":11,"nctId":262,"briefTitle":263,"officialTitle":264,"acronym":4,"eligibilityCriteria":265,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":266,"targetDuration":4,"studyType":21,"phases":268,"briefSummary":270,"conditions":271,"keywords":4,"overallStatus":61,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":162},"100486950","treatment-of-advanced-malignant-solid-tumors-with-claudin182car-t-100486950","NCT05620732","Treatment of Advanced Malignant Solid Tumors With Claudin18.2CAR-T","Efficacy and Safety of Claudin18.2CAR-T in Advanced Pancreatic Cancer and Gastric Carcinoma","Inclusion Criteria:\n\n1. Age 18-75 (≥ 18, ≤ 75), regardless of gender;\n2. Subjects voluntarily participate in the study, and they or their legal guardians sign the Informed Consent Form;\n3. Non resectable, locally late recurrent or metastatic gastric cancer or pancreatic cancer confirmed by histopathology; Patients with gastric cancer or pancreatic cancer diagnosed as stage III or IV according to the TNM staging system of the American Joint Commission on Cancer (AJCC) (8th edition in 2017);\n4. According to RECIST 1.1 standard, there are clearly measurable and evaluable lesions;\n5. Immunohistochemical staining confirmed that Claudin 18.2 was moderately and highly expressed in tumor tissues;\n6. Subjects must have received the first and second line standard treatment scheme;\n7. The subject must not be suitable for receiving radical treatment methods, such as radical chemotherapy and radiotherapy and\u002For surgery\u002Fimmunosuppressant at the checkpoint, or refuse surgical resection\n8. Within 2 weeks before cell therapy, no antibody drugs were used;\n9. ECOG score is 0-2;\n10. The subjects had no contraindication for peripheral blood collection;\n11. The expected survival period is more than 3 months.\n\nExclusion Criteria:\n\n1. People who have a history of allergy to any component in cell products;\n2. The following conditions occur in blood routine examination: WBC ≤ 1 × 109\u002FL, absolute value of central granulocyte ANC ≤ 0.5 × 109\u002FL, absolute value of lymphocyte ALC ≤ 0.5 × 109\u002FL , PLT≦25 × 109\u002FL ；\n3. The following conditions occur in laboratory testing: including but not limited to, total serum bilirubin ≥ 1.5mg\u002Fdl; Serum ALT or AST is more than 2.5 times of the upper limit of normal; Blood creatinine ≥ 2.0mg\u002Fdl;\n4. According to the NYHA cardiac function grading standard, patients with cardiac insufficiency belong to Grade III or IV; Or left ventricular ejection fraction (LVEF)\\\u003C50% by echocardiography;\n5. Pulmonary function is abnormal, and the saturation of blood oxygen under indoor air is less than 92%;\n6. Myocardial infarction, cardiac angioplasty or stenting, unstable angina pectoris, or other serious heart diseases clinically within 12 months before enrollment;\n7. Grade 3 hypertension and poor blood pressure control after drug treatment;\n8. Have suffered from brain trauma, consciousness disorder, epilepsy, relatively serious cerebral ischemia or cerebral hemorrhage disease in the past;\n9. Patients with autoimmune diseases, immunodeficiency or other patients requiring immunosuppressive treatment;\n10. There is uncontrolled active infection;\n11. Have used any CAR-T cell product or other genetically modified T cell therapy before;\n12. Live vaccine inoculation within 4 weeks before enrollment;\n13. HIV, HBV, HCV and TPPA\u002FRPR positive persons, and HBV carriers;\n14. Subjects have a history of alcohol abuse, drug abuse or mental illness;\n15. Subjects have participated in any other clinical research within 3 months before joining this clinical research;\n16. Female subjects have any of the following conditions: a) are in pregnancy\u002Flactation; Or b) having a pregnancy plan during the trial; Or c) is fertile and unable to take effective contraceptive measures;\n17. The investigator believes that there are other circumstances that are not suitable for the subject to participate in this study",{"count":267,"type":20},20,[269],"NA","The efficacy of advanced pancreatic cancer and gastric cancer needs to be further improved. Claudin is a kind of integrin membrane protein in the tight junction between epithelium and endothelium, which is highly expressed in gastric cancer and pancreatic cancer. Preclinical studies suggest that Claudin18.2CAR-T can effectively improve the remission rate of patients with advanced solid tumors.",[102,42],"2022-11-17",{"date":274,"type":65},"2022-11-22",{"date":276,"type":65},"2022-10-01",{"date":278,"type":20},"2028-10-31",{"name":280,"class":137},"Shenzhen University General Hospital",{"id":282,"slug":283,"hasResults":11,"nctId":284,"briefTitle":285,"officialTitle":286,"acronym":4,"eligibilityCriteria":287,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":214,"enrollmentInfo":288,"targetDuration":4,"studyType":21,"phases":290,"briefSummary":291,"conditions":292,"keywords":4,"overallStatus":226,"whyStopped":4,"lastUpdateSubmitDate":295,"lastUpdatePostDateStruct":296,"startDateStruct":298,"completionDateStruct":300,"leadSponsor":302,"locationsCount":4},"100460069","phase-3-study-evaluating-neoadjuvant-immunotherapy-increasing-cd8-cell-infiltration-in-advance-gastric-adenocarcinoma-100460069","NCT05270824","Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma","Study Evaluating Neoadjuvant Immunotherapy Increasing CD8+ Cell Infiltration in Advance Gastric Adenocarcinoma : a Single Randomized Controlled Trial","Inclusion Criteria:\n\n1. Age from 18 to 75 years\n2. Primary gastric adenocarcinoma (papillary, tubular, mucinous, signet ring cell, or poorly differentiated) confirmed pathologically ；\n3. CT\u002FMRI, PET-CT, or laparoscopic exploration should be performed before surgery to confirm the diagnosis of stage ≥cT2 or N+；\n4. Patients who have not received other treatments such as surgery, radiotherapy, chemotherapy, targeted therapy or immunotherapy；\n5. Performance status of 0 or 2 on Eastern Cooperative Oncology Group scale (ECOG)；\n6. Estimated survival time was over 3 months；\n7. No serious heart, lung and liver dysfunction; no jaundice and gastrointestinal obstruction; no acute infection;；\n8. The major organs are functioning normally and meet the following criteria:\n\n(1) Blood routine examination should meet the requirements (no blood transfusion within 14 days):\n\n1. HB≥100g\u002FL，\n2. WBC≥3×109\u002FL\n3. ANC≥1.5×109\u002FL，\n4. PLT≥100×109\u002FL； （2）Biochemical tests must meet the following criteria：\n\na. BIL \\\u003C1.5×upper limit of normal (ULN)， b. ALT and AST\\\u003C2.5ULN，GPT≤1.5×ULN； c. Cr≤1ULN，Ccr \\>60ml\u002Fmin 9. Fertile women must have taken a pregnancy test (serum) within 7 days prior to enrollment with negative results and be willing to use an appropriate method of contraception during the trial period and 8 weeks after the last trial drug; For men, they should be surgically sterilized or agree to use the appropriate method of contraception during the trial period and 8 weeks after the last administration of the trial drug 10. Did not participate in other clinical studies before and during treatment 11. Subjects voluntarily joined the study and signed informed consent with good compliance and follow-up\n\nExclusion Criteria:\n\n1. History of other malignant disease within past five years；\n2. History of immunodeficiency, including HIV positive, or other acquired congenital immunodeficiency disease, or a history of organ transplantation and allogeneic bone marrow transplantation；\n3. Contraindications to surgery and chemotherapy, or whose physical condition and organ function do not allow for major abdominal surgery\n4. Distant metastases；\n5. Accompanied by severe heart, lung, liver and kidney diseases; neurological and mental diseases; jaundice and accompanied by severe infection；\n6. Women during pregnancy or breast-feeding；\n7. Patients with high blood pressure that cannot be reduced to the normal range after antihypertensive drug treatment (systolic blood pressure\\>140 mmHg, diastolic blood pressure\\>90 mmHg);\n8. Suffering from coronary heart disease of grade I or above, arrhythmia (including QTc interval prolongation \\> 450 ms in men and \\> 470 ms in women), and cardiac insufficiency;\n9. Patients with a clear tendency to gastrointestinal bleeding, including the following conditions: patients with locally active ulcer lesions, fecal occult blood (++), and history of melena and hematemesis within 2 months; patients with abnormal coagulation function (INR\\> 1.5, APTT\\>1.5 ULN);\n10. Patients with a history of cardiovascular and cerebrovascular diseases who are still taking oral thrombolytics or anticoagulants;\n11. Patients with positive urine protein (urinary protein test 2+ or above, or 24-hour urine protein quantitative\\> 1.0g;\n12. Multiple factors affect oral drugs (such as inability to swallow, persistent uncontrollable nausea and vomiting, chronic diarrhea and intestinal obstruction, etc.);\n13. Those who have allergic reactions to the drugs in this study;\n14. The researcher believes that it is not suitable for inclusion.",{"count":289,"type":20},120,[150],"Focusing on the clinical question of whether patients with advanced gastric cancer can benefit from immunotherapy, this project intends to detect the degree of CD8+ tumor-infiltrating lymphocyte infiltration in patients with advanced gastric cancer before and after receiving neoadjuvant combined immunotherapy and neoadjuvant therapy alone. To explore the evolving nature of tumor immune response before and after neoadjuvant therapy for gastric cancer, and quantitatively present it through chemical immunohistochemical techniques to achieve a more accurate diagnosis and treatment and improve the long-term efficacy of patients.",[42,293,294],"CD8+ Tumor Infiltrating Lymphocytes","Neoadjuvant Immunotherapy","2022-02-26",{"date":297,"type":65},"2022-03-08",{"date":299,"type":20},"2022-03-01",{"date":301,"type":20},"2027-03-01",{"name":303,"class":137},"Fujian Medical University"]